文献速递银屑病与炎症性皮肤病

富马酸二甲酯治疗中重度斑块状银屑病的生活质量结局:BRIDGE 研究事后分析

Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-10-17

BRIDGE 研究事后分析纳入 671 例中重度斑块状银屑病患者,随机接受富马酸二甲酯(DMF)、富马酸酯类固定复方(FAE)或安慰剂治疗 16 周。结果显示 DMF 在改善第 16 周 DLQI 结局方面优于安慰剂(P < 0.001),与 FAE 无显著差异(P > 0.05),且基线疾病严重程度不影响 DLQI 结局;第 8 周 PASI 50/75 应答及 PASI ≤ 3 和/或 PGA 0-1 应答可预测第 16 周 DLQI 0-1。

要点

  • DMF 改善第 16 周 DLQI 优于安慰剂,与 FAE 无显著差异。
  • 基线疾病严重程度不影响第 16 周 DLQI 结局。
  • 第 8 周 PASI 50/75 或 PASI ≤3/PGA 0-1 应答预测第 16 周 DLQI 0-1。

核心结论

  • DMF 较安慰剂显著改善 DLQI 结局,且不受基线疾病严重程度影响。
  • 第 8 周疗效应答(PASI 50/75、PASI ≤3 和 PGA 0-1)可预测 DMF 和 FAE 治疗患者第 16 周的生活质量结局。

研究设计与样本

  • BRIDGE 研究的事后分析,随机、双盲、III 期研究。
  • 全分析集共 671 例患者,随机接受 DMF(267 例)、FAE(273 例)或安慰剂(131 例)治疗 16 周。

主要发现

  • 第 16 周 DLQI 结局:DMF 优于安慰剂(P < 0.001),与 FAE 无显著差异(P > 0.05)。
  • 基线疾病严重程度不影响第 16 周 DLQI 结局。
  • 在 DMF 和 FAE 治疗患者中,第 8 周 PASI 50/75 应答者较非应答者第 16 周 DLQI 应答更好(P < 0.05)。
  • 第 8 周 PASI ≤ 3 和/或 PGA 0-1 应答者较非应答者更可能在第 16 周报告 DLQI 0-1(P < 0.05)。

关键数值与推荐

  • DLQI 0-1 定义为「对患者生活无影响」。
  • DMF 最大日剂量为 720 mg。
  • FAE 采用逐渐上调剂量。

临床怎么用

  • DMF 可改善中重度斑块状银屑病患者的生活质量,疗效不受基线严重程度影响。
  • 治疗第 8 周的 PASI 50/75 或 PASI ≤3/PGA 0-1 应答可提示第 16 周生活质量改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis is a chronic inflammatory skin disease associated with quality of life (QoL) impairment. BRIDGE was a randomized, double-blind, phase III study comparing the efficacy and safety of dimethylfumarate (DMF) with a fixed combination of fumaric acid esters (FAE) or placebo for the treatment of moderate-to-severe psoriasis. OBJECTIVES: This post hoc analysis investigated treatment effect on QoL overall and by patient subgroups categorized by disease severity. Week 8 efficacy responses were also investigated as possible predictors of Week 16 Dermatology Life Quality Index (DLQI) outcomes. METHODS: Patients were randomized to receive a maximum daily dose of 720 mg of DMF, FAE (gradual up-titration) or placebo for 16 weeks. Psoriasis Area Severity Index, Body Surface Area, Physician's Global Assessment and DLQI were assessed at baseline, Weeks 8 and 16. DLQI 0-1 indicated 'no effect on patient life'. Associations between baseline severity, Week 16 DLQI and Week 8 efficacy (as observed cases) were also examined. RESULTS: At baseline, 671 patients were included in the full analysis set (267 randomized to DMF, 273 to FAE and 131 to placebo). DMF was superior to placebo (P < 0.001) and not significantly different to FAE regarding Week 16 DLQI outcomes (P > 0.05). Baseline disease severity did not impact DLQI outcomes at Week 16. In DMF- and FAE-treated patients, Week 8 PASI 50/75 responders reported better DLQI responses at Week 16 vs non-responders (P < 0.05). Week 8 PASI ≤ 3 and/or PGA 0-1 responders were also more likely to report DLQI 0-1 at Week 16 vs non-responders (P < 0.05). CONCLUSION: Dimethylfumarate significantly improved DLQI outcomes vs. placebo and was not affected by baseline disease severity. Efficacy responses (PASI 50/75, PASI ≤3 and PGA 0-1) as early as Week 8 were predictive of QoL outcomes at Week 16 in DMF- and FAE-treated patients.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. van de Kerkhof PCM, Loewe R, Mrowietz U, et al. Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study. J Eur Acad Dermatol Venereol. 2019. PMID: 31465585. doi:10.1111/jdv.15922

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。